GTreeBNT Obtains FDA Compassionate Use Approval for 'OKN-007'

[Asia Economy Reporter Jang Hyowon] Oblato, a U.S. subsidiary of GTreeBNT, announced on the 19th that it has received FDA approval for the expanded access of OKN-007, which is being developed as a treatment for glioblastoma (GBM), for the additional indication of brain glioma.

GTreeBNT previously received FDA approval in December last year to enter clinical trials targeting pediatric patients with DIPG, and is currently discussing the progression of formal clinical trials with a consortium of U.S. pediatric cancer specialty hospitals.

Expanded Access (EA) is a system that permits the use of investigational new drugs that are still under development and have not yet obtained marketing approval, when there are no adequate treatments available for life-threatening, long-term, or severe diseases.

Among these, iEAP (individual Expanded Access Program) allows the administration of investigational drugs to a wide range of patients across multiple medical institutions. The iEAP patients eligible for OKN-007 include pediatric and adult patients with DIPG-like conditions as well as various types of gliomas, including malignant gliomas originating from the thalamus, hypothalamus, brainstem, midbrain, pons, medulla oblongata, bone marrow, and spinal cord, as well as neuroblastomas, anaplastic neuroblastomas, and other similar diseases.

Additionally, a GTreeBNT representative stated, “iEAP not only aims to provide treatment opportunities to many patients but also that data obtained through iEAP, combined with results from formal clinical trials, have been used in numerous cases to obtain approval for orphan drugs,” adding, “This aligns with our development strategy for GBM and DIPG.”

This content was produced with the assistance of AI translation services.